# A Study To Evaluate The Safety Of CMTX-101 In People With Cystic Fibrosis

> **NCT06159725** · PHASE1,PHASE2 · COMPLETED · sponsor: **Clarametyx Biosciences, Inc.** · enrollment: 43 (actual)

## Conditions studied

- Persistent Infection
- Cystic Fibrosis

## Interventions

- **DRUG:** CMTX-101
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06159725
- **Lead sponsor:** Clarametyx Biosciences, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-06-24
- **Primary completion:** 2025-11-14
- **Final completion:** 2025-11-14
- **Target enrollment:** 43 (ACTUAL)
- **Last updated:** 2026-05-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06159725

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06159725, "A Study To Evaluate The Safety Of CMTX-101 In People With Cystic Fibrosis". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT06159725. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*